{"slideshow_credits": null, "snippet": "The merger proxy for Mallinckrodt&#8217;s $5.6 billion bid for Questcor Pharmaceuticals does not include reports of incidents involving Acthar, Questcor&#8217;s immune-system drug and its biggest product.", "abstract": "Merger proxy for Mallinckrodt\u2019s $5.6 billion bid for Questcor Pharmaceuticals does not include reports of incidents involving Acthar, immune-system drug that is Questcor\u2019s biggest product; incidents include 20 deaths and six disabilities since 2012; issue is just one of many hanging over Questcor, which also faces inquiries concerning marketing practices and labeling.", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Gretchen", "role": "reported", "lastname": "MORGENSON", "rank": 1, "organization": ""}], "original": "By GRETCHEN MORGENSON", "contributor": ""}, "web_url": "http://www.nytimes.com/2014/06/13/business/a-drugs-risks-are-left-out-in-discussion-of-questcor-deal.html", "lead_paragraph": "The merger proxy for Mallinckrodt&#8217;s $5.6 billion bid for Questcor Pharmaceuticals does not include reports of incidents involving Acthar, Questcor&#8217;s immune-system drug and its biggest product.", "headline": {"main": "Drug Merger Discussion Leaves Out a Key Risk", "print_headline": "Drug Merger Discussion Leaves Out a Key Risk"}, "_id": "539a026f38f0d83101a1cf77", "word_count": "1371", "multimedia": [{"height": 126, "url": "images/2014/06/13/business/13quest-pic/13quest-pic-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2014/06/13/business/13quest-pic/13quest-pic-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 400, "url": "images/2014/06/13/business/13quest-pic/13quest-pic-articleLarge.jpg", "legacy": {"xlarge": "images/2014/06/13/business/13quest-pic/13quest-pic-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2014/06/13/business/13QUEST/13QUEST-thumbStandard.jpg", "legacy": {"thumbnail": "images/2014/06/13/business/13QUEST/13QUEST-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2014-06-13T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "N", "rank": "5"}, {"value": "Mergers, Acquisitions and Divestitures", "name": "subject", "is_major": "N", "rank": "3"}, {"value": "Mallinckrodt Plc.", "name": "organizations", "is_major": "Y", "rank": "1"}, {"value": "Questcor Pharmaceuticals Inc", "name": "organizations", "is_major": "Y", "rank": "2"}, {"value": "Food and Drug Administration", "name": "organizations", "is_major": "N", "rank": "4"}], "blog": [], "subsection_name": null, "type_of_material": "News"}